DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20173637

Azidothymidine induces severe hematological toxicity and hepatic injury in Charles Foster rats

Rajat Pandey, Ramakant Singh

Abstract


Background: The present study aimed at evaluating the effects of azidothymidine (AZT) on hematologic and biochemical parameters in Charles Foster rats.

Methods: Twelve adult healthy Charles Foster rats comprising of six male and six females were selected for study. Test rodents were divided into four groups containing three rodents each. Three males and three females served as control and remaining received AZT drug. Rodents were acclimatized for 10 days and drug was administered for 28 days. After the completion of drug administration, blood samples were collected and analyzed for hematologic parameters, i.e., Hemoglobin (Hb), Packed cell volume (PCV), red blood cell (RBC), Mean corpuscular hemoglobin concentration (MCHC), total leukocyte count (TLC), Mean corpuscular volume (MCV), Platelet count (Plt) using a Fully Automatic Fully Digital Hematology Cell Counter. In addition, biochemical parameters, were measured to assess the effects of AZT on rodent physiology. In-vivo histopathological studies were also performed on vital organs of rodents to understand the effects of drug at tissue level.

Results: When compared with the control group, the data indicated a outstanding decrease in Hb, PCV, RBC, TLC and platelets in all test groups, whereas MCHC did not show any major reduction but MCV data suggested a slight increase. Among biochemical parameters, aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase (ALP). were found to be remarkably elevated along with elevated bilirubin and reduced albumin, pointing towards a possible liver damage which was later corroborated by liver histopathological study.

Conclusions: Above results indicate azidothymidine to be a myelosuppresive and hepatotoxic drug and its usage as an anti-retro viral during highly active anti-retro viral therapy (HAART) regime should be strictly monitored.


Keywords


AZT, Hematotoxicity, Hepatotoxicity, Subacute toxicity

Full Text:

PDF

References


Sepkowitz KA. AIDS--the first 20 years. N Engl J Med. 2001;344(23):1764-1772.

WHO | HIV/AIDS. WHO. Available at: http://www.who.int/mediacentre/factsheets/fs360/en/. Accessed May 1, 2017.

HIV Basics CDC. Available at: https://www.cdc.gov/hiv/basics/statistics.html. Accessed May 1, 2017.

Gottlieb MS, Schroff R, Schanker HM, Weisman JD, Fan PT, Wolf RA, et al. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. New England Journal of Medicine. 1981 Dec 10;305(24):1425-31.

Masur H, Michelis MA, Greene JB. An outbreak of community-acquired Pneumocystis carinii pneumonia: initial manifestation of cellular immune dysfunction. N Engl J Med. 1981;305(24):1431-8.

Coffin J, Haase A, Levy JA, Montagnier L, Oroszlan S, Teich N, Temin H, Toyoshima K, Varmus H, Vogt P. What to call the AIDS virus?. Nature. 1986;321(6065):10.

Rerks-Ngarm S, Paris RM, Chunsutthiwat S, Premsri N, Namwat C, Bowonwatanuwong C, et al. Extended evaluation of the virologic, immunologic, and clinical course of volunteers who acquired HIV-1 infection in a phase III vaccine trial of ALVAC-HIV and AIDSVAX B/E. The Journal of infectious diseases. 2012 Jul 26;207(8):1195-205.

Amin NM. Zidovudine for treating AIDS. What physicians need to know. Postgrad Med. 1989;86(1):195-6,201-8.

Vince R, Hua M, Brownell J, Daluge S, Lee F, Shannon WM, et al. Potent and selective activity of a new carbocyclic nucleoside analog (carbovir: NSC 614846) against human immunodeficiency virus in vitro. Biochemical and biophysical research communications. 1988 Oct 31;156(2):1046-53.

FDA. HIV/AIDS History of Approvals - HIV/AIDS Historical Time Line. 1981-1990. Available at: https://www.fda.gov/forpatients/illness/hivaids/history/ucm151074.htm. Accessed May 1, 2017.

Horwitz JP, Chua J, Noel M. Nucleosides. V. The Monomesylates of 1-(2’-Deoxy-β-D-lyxofuranosyl) thymine 1,2. J Org Chem. 1964;29(7):2076-8.

Akanbi MO, Scarci K, Taiwo B, Murphy RL. Combination Nucleoside/ Nucleotide Reverse Transcriptase Inhibitors. Expert Opin Pharmacother. 2012;13(1):65.

Richman DD, Fischl MA, Grieco MH. The Toxicity of Azidothymidine (AZT) in the Treatment of Patients with AIDS and AIDS-Related Complex. N Engl J Med. 1987;317(4):192-7.

Wickramasinghe SN. Diagnosis of megaloblastic anaemias. Blood Rev. 2006;20(6):299-318.

Levine AM, Berhane K, Masri-Lavine L, Sanchez M, Young M, Augenbraun M, et al. Prevalence and correlates of anemia in a large cohort of HIV-infected women: Women's Interagency HIV Study. Journal of acquired immune deficiency syndromes (1999). 2001 Jan;26(1):28-35.

Ukoha U, Umeasalugo K, Dimkpa U, Ndukwe G, Anyabolu A, Emefo L. Effects of zidovudine on hemostatic and hematologic parameters in adult rats. J Exp Integr Med. 2015;5(2):85.

Raghu R, Jesudas B, Bhavani G, Ezhilarasan D, Karthikeyan S. Silibinin mitigates zidovudine-induced hepatocellular degenerative changes, oxidative stress and hyperlipidaemia in rats. Hum Exp Toxicol. 2015;34(11):1031-42.

Okwa IB, Akindele AJ, Agbaje EO, Oshinuga OT, Anunobi CC, Adeyemi OO. Effect of subclinical, clinical and supraclinical doses of calcium channel blockers on models of drug-induced hepatotoxicity in rats. EXCLI J. 2013;12:231-50.

Agarwal D, Chakravarty J, Chaube L, Rai M, Agrawal NR, Sundar S. High incidence of zidovudine induced anaemia in HIV infected patients in eastern India. 2010. Available at: http://imsear.li.mahidol.ac.th/handle/123456789/135598. Accessed March 21, 2017.

Langtry HD, Campoli-Richards DM. Zidovudine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs. 1989;37(4):408-50.

Lutton JD, Abraham NG, Drummond GS, Levere RD, Kappas A. Zinc porphyrins: Potent inhibitors of hematopoieses in animal and human bone marrow. Proc Natl Acad Sci U S A. 1997;94(4):1432-6.

Adewale AO, Jubril OO, Oluwaseun HI, Selimot HA, Ayoola AR. Effects of a single pill 3-drug combination of lamivudine, nevirapine and zidovudine on blood parameters and liver histology in female wistar rats. American Journal of Medicine and Medical Sciences. 2012;2(4):71-4.

Gallicchio VS, Hughes NK, Tse KF. Prevention of hematopoietic myeloid and megakaryocyte toxicity associated with zidovudine in vivo in mice with recombinant GM-CSF. Growth Regul. 1994;4(2):41-7.

Gallicchio VS, Hughes NK, Tse KF, Gaines H. Prevention of the hematopoietic toxicity associated with zidovudine in vivo with. Growth Factors Chur Switz. 1993;9(3):177-83.

Shaunak S, Bartlett J. Zidovudine-induced neutropenia: are we too cautious? The Lancet. 1989;334(8654):91-2.

Awodele O, Agbaje EO, Adesina EA, Akintonwa A. Hepatoprotective role of neutrosec R on hepatic damage induced by combination of zidovudine and combined anti-tuberculous agents in rats. Tokai J Exp Clin Med. 2011;36(2):31-6.

Sallie R, Michael Tredger J, Williams R. Drugs and the liver part 1: Testing liver function. Biopharm Drug Dispos. 1991;12(4):251-9.

Jones AL. Hepatology. A Text Book of Liver Disease. In: Hepatology, Z.D. and Boyer, T.D., Eds. Philadelphia: W.B. Saunders; 1982.

Sharma PO. Clinical Biochemistry of Hepatotoxicity. J Clin Toxicol. 2014;4(1).

Mehana EE, Meki ARMA, Fazili KM. Ameliorated effects of green tea extract on lead induced liver toxicity in rats. Exp Toxicol Pathol Off J Ges Toxikol Pathol. 2012;64(4):291-5.